Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Abstract
Highly potent, but poorly water-soluble, drug candidates are common outcomes of contemporary drug discovery programmes and present a number of challenges to drug development - most notably, the issue of reduced systemic exposure after oral administration. However, it is increasingly apparent that formulations containing natural and/or synthetic lipids present a viable means for enhancing the oral bioavailability of some poorly water-soluble, highly lipophilic drugs. This Review details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drugs and provides a perspective on the possible future applications of lipid-based delivery systems. Particular emphasis has been placed on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first-pass drug metabolism) and alter enterocyte-based drug transport and disposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“This route becomes quantitatively relevant only for compounds that combine high lipophilicity with appreciable long-chain triglyceride solubility, for which a log P greater than 5 and a lipid solubility above approximately 50 mg/g are commonly cited as approximate thresholds [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“Because lymphatic delivery reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28,29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“For highly lipophilic drugs, a fraction of the absorbed dose can bypass the portal circulation entirely and reach the systemic circulation via the intestinal lymphatics, associated with triglyceride-rich lipoproteins (chylomicrons) assembled within the enterocyte [28,29].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“The extent of transport is highly sensitive to prandial state and to the type and quantity of co-administered lipid, which differ across preclinical study designs and between the fasted conditions typical of first-in-human protocols and the fed conditions under which lymphatic transport is greatest [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“This is especially the case when potent, but highly lipophilic, drug candidates arise from complex chemical scaffolds and multiple high-throughput activity screen”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Items 701–800 of 1,003
Alqahtani, S., Alayoubi, A. Y., Nazzal, S., Sylvester, P. W., & Kaddoumi, A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9481-7 · Cited by 42
Miao, Y., Chen, G., Ren, L., & Pingkai, O. (2014) · Drug Delivery · doi:10.3109/10717544.2014.950768 · Cited by 42
“However, owing to their smaller particle size, nanoemulsions reconstituted from SNEDDS can be digested quickly, thus achieving much quick absorption (Porter et al., 2007; Pouton & Porter, 2008; Khan et al., 2014), which may remain the problem of peak and valley fluctuations of plasma drug levels…”
BackgroundAttia, M. F., Anton, N., Akasov, R., Chiper, M., Арнольдовна, М. Е., & Vandamme, T. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1813-0 · Cited by 42
Wang, Q., Li, C., Ren, T., Chen, S., Ye, X., Guo, H., He, H., Zhang, Y. X., Yin, T., Liang, X., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00612 · Cited by 42
Yang, S. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1116-2 · Cited by 42
“A great number of drug candidates have been discarded in pre-clinical stage due to their improper solubility (Porter et al., 2007).”
BackgroundLawless, E., Griffin, B. T., O’Mahony, A., & O’Driscoll, C. M. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1578-x · Cited by 41
“The suggested mechanisms of absorption enhancement include; improved solubilisation [2, 3], increased membrane permeability, inhibition of pre-systemic drug metabolism and promotion of mesenteric lymphatic transport [4, 5].”
BackgroundVithani, K., Hawley, A. M., Jannin, V., Pouton, C. W., & Boyd, B. J. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0036-6 · Cited by 41
Soni, K., Mujtaba, M. A., & Kohli, K. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.05.015 · Cited by 41
Yao, X., Nie, K., Chen, Y., Jiang, F., Kuang, Y., Yan, H., Fang, Y., Yang, H., Nishinari, K., & Phillips, G. O. (2017) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2017.07.043 · Cited by 41
Neuroprotective Natural Molecules, From Food to Brain
González-Fuentes, J., Selva, J. S., Moya‐López, C., Castro‐Vázquez, L., Lozano, M. V., Marcos, P., Plaza-Oliver, M., Robledo, V. R., Santander-Ortega, M. J., Villaseca-González, N., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00721 · Cited by 41
Recent Advances in Engineering of Lipid Drug Conjugates for Cancer Therapy
Sreekanth, V., & Bajaj, A. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00689 · Cited by 41
Chen, L., Liang, R., YOKOYAMA, W. H., Alves, P. L. D. S., Pan, J., & Zhong, F. (2020) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2020.105847 · Cited by 41
Supersaturated Lipid-Based Formulations to Enhance the Oral Bioavailability of Venetoclax
Koehl, N. J., Henze, L. J., Kuentz, M., Holm, R., & Griffin, B. T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060564 · Cited by 41
“LBFs may improve oral bioavailability via a number of mechanisms including avoidance of a drug dissolution step, an increased extent of drug solubilisation in intestinal fluids, lipid excipient-mediated increased intestinal permeability as well as possible enhancement of lymphatic uptake from the gastrointestinal trac…”
BackgroundLipids for Taste masking and Taste assessment in pharmaceutical formulations
Banerjee, S., Joshi, U., Singh, A., & Saharan, V. A. (2020) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.105031 · Cited by 41
Kenechukwu, F. C., Nnamani, D. O., Duhu, J. C., Nmesirionye, B. U., Momoh, M. A., Akpa, P. A., & Attama, A. A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09099 · Cited by 41
“This influence could be by altering the composition and character of the intestinal milieu, recruiting intestinal lymphatic drug transport, and interaction with enterocyte-based transport processes or other physiological effects, such as retarded gastric emptying [61].”
BackgroundZheng, H., Chen, B., & Rao, J. (2022) · Food & Function · doi:10.1039/d1fo04433h · Cited by 41
Preparation, modelling, characterization and release profile of vitamin D3 nanoemulsion
Jan, Y., Al‐Keridis, L. A., Malik, M., Haq, A., Ahmad, S., Kaur, J., Adnan, M., Alshammari, N., Ashraf, S. A., & Panda, B. P. (2022) · LWT · doi:10.1016/j.lwt.2022.113980 · Cited by 41
Han, S., Hu, L., Quach, T., Simpson, J. S., Trevaskis, N. L., & Porter, C. J. H. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1579-9 · Cited by 41
Self-citationBiorelevant media resistant co-culture model mimicking permeability of human intestine
Antoine, D., Pellequer, Y., Tempesta, C., Lorscheidt, S., Kettel, B., Tamaddon, L., Jannin, V., Demarne, F., Lamprecht, A., & Béduneau, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.028 · Cited by 41
“However, a study in healthy human volunteers emphasized significant differences between FaSSIF and FeSSIF compared with the in-vivo conditions (Porter et al., 2007).”
BackgroundLiu, D., Liu, C., Zou, W., & Zhang, N. (2009) · Journal of Nanoparticle Research · doi:10.1007/s11051-009-9648-4 · Cited by 41
Development and optimization of self microemulsifying drug delivery of domperidone
Laddha, P., Suthar, V., & Butani, S. (2011) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502011000100009 · Cited by 41
Nasr, M., & Dawoud, M. (2016) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2016.06.011 · Cited by 41
Supramolecular structures in lipid digestion and implications for functional food delivery
Salentinig, S. (2019) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2019.02.002 · Cited by 41
Solid Lipid Nanoparticles for Drug Delivery
Joseph, S., & Bunjes, H. (2013) · Wiley eBooks · doi:10.1002/9781118444726.ch4 · Cited by 41
Smart pills and drug delivery devices enabling next generation oral dosage forms
Milián-Guimerá, C., McCabe, R., Thamdrup, L. H. E., Ghavami, M., & Boisen, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.041 · Cited by 40
El-Meligy, M. A., El-Monaem, E. M. A., Eltaweil, A. S., Eldin, M. S. M., Ziora, Z. M., Heydari, A., & Omer, A. M. (2024) · Molecules · doi:10.3390/molecules29102393 · Cited by 41
“Novel oral formulations containing non-cytotoxic targeted agents [15], lipid-based formulations [16], permeation enhancers, and gastro-retentive dosage forms [16,17] have the potential to address these challenges.”
BackgroundGriffin, B. T., & O’Driscoll, C. M. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.128 · Cited by 40
Borkar, N., Xia, D., Holm, R., Gan, Y., Müllertz, A., Yang, M., & Mu, H. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.022 · Cited by 40
“…digestion and solubilisation data at lower lipid masses (approximately 5 mg/mL of digestion medium) were consistent with the in vivo data where the bioavailability of halofantrine after oral administration of longchain triglyceride (LCT) solution was higher than MCT solution (Porter et al., 2004).”
ResultRao, S., Tan, A., Thomas, N., & Prestidge, C. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.013 · Cited by 40
Matzneller, P., Kussmann, M., Eberl, S., Maier‐Salamon, A., Jäger, W. R., Bauer, M., Langer, O., Zeitlinger, M. A., & Poeppl, W. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0474-x · Cited by 40
“Interestingly, the presence of bile salts, which is typically increased in the post-prandial phase [37], is known to enhance the solubilisation and oral absorption of”
Han, J., Gu, L., Zhang, R., Shang, W., Yan, J., McClements, D. J., Wu, H., Zhu, B., & Xiao, H. (2018) · Food & Function · doi:10.1039/c8fo01390j · Cited by 40
Self-microemulsifying delivery system for improving bioavailability of water insoluble drugs
Yan, B., Ma, Y., Guo, J., & Wang, Y. (2020) · Journal of Nanoparticle Research · doi:10.1007/s11051-019-4744-6 · Cited by 40
Kontogiannidou, E., Meikopoulos, T., Gika, H., Panteris, E., Vizirianakis, I. S., Müllertz, A., & Fatouros, D. G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080699 · Cited by 40
“SNEDDS induce the formation of oil droplets, which in turn may facilitate the transport of the active across the intestinal membrane [11].”
BackgroundZhao, M., Shen, P., Zhang, Y., Zhong, M., Zhao, Q., & Zhou, F. (2021) · ACS Food Science & Technology · doi:10.1021/acsfoodscitech.0c00005 · Cited by 40
Rebelatto, E. R. L., Rauber, G. S., & Caon, T. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122727 · Cited by 40
Wan, L., Zhang, T., Ye, Y., Zhang, X., & Wu, B. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.10.011 · Cited by 40
Stillhart, C., Imanidis, G., Griffin, B. T., & Kuentz, M. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1432-1 · Cited by 40
“Additionally, lipid excipients may increase drug permeability across the intestinal membrane and promote drug uptake via the intestinal lymphatics (1).”
BackgroundNiederquell, A., & Kuentz, M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.005 · Cited by 40
Akhtar, M., Imam, S. S., Ahmad, M. A., Najmi, A. K., Mujeeb, M., & Aqil, M. (2014) · Drug Delivery · doi:10.3109/10717544.2014.886640 · Cited by 40
“lipid carrier systems as a means to improve the drug solubilization and permeation across the GI barrier (Porter et al., 2007; Janga et al., 2012).”
BackgroundSato, Y., Kobayashi, M., Itagaki, S., Hirano, T., Noda, T., Mizuno, S., Sugawara, M., & Iseki, K. (2011) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.746 · Cited by 40
Dahan, A., Mendelman, A., Amsili, S., Ezov, N., & Hoffman, A. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.09.005 · Cited by 40
In Vivo Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems
Sassene, P. J., Michaelsen, M. H., Mosgaard, M. D., Jensen, M. K., Van Den Broek, E., Wasan, K. M., Mu, H., Rades, T., & Müllertz, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00413 · Cited by 38
Yao, M., McClements, D. J., Zhao, F.-Q., Craig, R. W., & Xiao, H. (2016) · NanoImpact · doi:10.1016/j.impact.2016.12.001 · Cited by 40
Trevaskis, N. L., Lee, G., Escott, A., Phang, K. L., Hong, J., Cao, E., Katneni, K., Charman, S. A., Han, S., Charman, W. N., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00458 · Cited by 39
“Rats and mice have continuous secretion of bile at a relatively constant rate as they lack a gall bladder whereas in dogs and humans, bile release from the gallbladder is intermittent and increases substantially when lipid is present in the intestine (Shiau et al., 1985; Porter et al., 2007).”
BackgroundSelf-citationHamdy, A., El‐Badry, M., Fathy, M., & El‐Sayed, A. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-71980-5 · Cited by 39
“The intraluminal processing of the triglycerides depends on the chain length of the lipids 57 .”
BackgroundRuela, A. L. M., Carvalho, F. C., & Pereira, G. R. (2015) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.10.016 · Cited by 39
Joyce, P. M., Gustafsson, H., & Prestidge, C. A. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.06.015 · Cited by 39
Kontogiannidou, E., Meikopoulos, T., Virgiliou, C., Bouropoulos, N., Gika, H., Vizirianakis, I. S., Müllertz, A., & Fatouros, D. G. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101524 · Cited by 39
Biomimetic oral targeted delivery of bindarit for immunotherapy of atherosclerosis
Yin, L., Peng, C., Tang, Y., Yuan, Y., Liu, J., Xiang, T., Liu, F., Zhou, X. W., & Li, X. (2020) · Biomaterials Science · doi:10.1039/d0bm00418a · Cited by 39
Karavasili, C., Andreadis, I. I., Tsantarliotou, M. P., Taitzoglou, I., Chatzopoulou, P. S., Katsantonis, D., Zacharis, C. K., Markopoulou, C. K., & Fatouros, D. G. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01765-2 · Cited by 39
Nemati, M., Azarbayjani, A. F., Al‐Salami, H., Asl, E. R., & Rasmi, Y. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3732 · Cited by 39
Chen, J., Zheng, J., Decker, E. A., McClements, D. J., & Xiao, H. (2015) · RSC Advances · doi:10.1039/c5ra13503f · Cited by 39
Lin, J., Novak, B., & Moldovan, D. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp208145b · Cited by 39
Li, Y., Song, J., Tian, N., Cai, J., Huang, M., Xing, Q., Wang, Y., Wu, C., & Hu, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.07.011 · Cited by 39
Jindal, A., Sharma, P. K., & Kumar, A. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2469751 · Cited by 38
Vinarova, L., Vinarov, Z., Tcholakova, S. S., Denkov, N. D., Stoyanov, S. D., & Lips, A. (2015) · Food & Function · doi:10.1039/c5fo00856e · Cited by 38
Human DNA Ligases: A Comprehensive New Look for Cancer Therapy
Singh, D. K., Krishna, S., Chandra, S., Shameem, M., Deshmukh, A. L., & Banerjee, D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21298 · Cited by 38
Joyce, P. M., Barnes, T. J., Boyd, B. J., & Prestidge, C. A. (2016) · RSC Advances · doi:10.1039/c6ra16028j · Cited by 38
Eleftheriadis, G. K., Mantelou, P., Karavasili, C., Chatzopoulou, P. S., Katsantonis, D., Irakli, M. N., Mygdalia, A., Vizirianakis, I. S., & Fatouros, D. G. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-018-1274-y · Cited by 40
“mance and bioavailability properties of the formulation (6,7).”
BackgroundDombach, J. L., Quintana, J. L. J., Nagy, T. A., Wan, C., Crooks, A. L., Yu, H., Su, C., Yu, E. W., Shen, J., & Detweiler, C. S. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009119 · Cited by 39
“Lipophilic compounds (LogP >2) tend to have low aqueous solubility and thus reduced bioavailability upon oral therapeutic delivery [92].”
BackgroundKhan, H., Nazir, S., Farooq, R. K., Khan, I. N., & Javed, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.806713 · Cited by 38
Fan, Z., Wu, J., Fang, X., & Sha, X. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.070 · Cited by 38
Weng, T., Qi, J., Lü, Y., Wang, K., Tian, Z., Hu, K., Yin, Z., & Wu, W. (2014) · Journal of Nanobiotechnology · doi:10.1186/s12951-014-0039-3 · Cited by 38
“Therefore, drugs can be solubilized in these secondary derivatives when lipidbased formulations are digested [31].”
BackgroundBile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel
Zhang, B., Xue, A., Zhang, C., Yu, J., Chen, W., & Sun, D. (2016) · Die Pharmazie · doi:10.31083/ph.2016.5184 · Cited by 38
Self-nanoemulsifying drug-delivery systems for potentiated anti-inflammatory activity of diacerein
Eltobshi, A. A., Mohamed, E. A., Abdelghani, G. M., & Nouh, A. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s178819 · Cited by 38
“In comparison with the Dcn-pretreated group, significantly (P,0.05) lower inflammation scores were observed on pretreatment with the optimized SNEDDSs.”
BackgroundInfluentialMeola, T. R., Schultz, H. B., Peressin, K. F., & Prestidge, C. A. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105357 · Cited by 38
In vitro–in vivo study of CoQ10-loaded lipid nanoparticles in comparison with nanocrystals
Piao, H., Ouyang, M., Xia, D., Quan, P., Xiao, W., Song, Y., & Cui, F. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.016 · Cited by 37
Taste masked lipid pellets with enhanced release of hydrophobic active ingredient
Vaassen, J., Bartscher, K., & Breitkreutz, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.013 · Cited by 37
A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib
Jacobsen, A.-C., Elvang, P. A., Bauer‐Brandl, A., & Brandl, M. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.11.003 · Cited by 38
Rangaraj, N., Shah, S., Maruthi, A. J., Pailla, S. R., Cheruvu, H. S., Dodoala, S., & Sampathi, S. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1476-y · Cited by 37
Ndayishimiye, J., Popat, A., Blaskovich, M. A. T., & Falconer, J. R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.002 · Cited by 37
Improving the bioavailability and bioactivity of garlic bioactive compounds via nanotechnology
Lu, X., Wang, C., Zhao, M., Wu, J., Niu, Z., Zhang, X., Simal‐Gándara, J., Süntar, I. P., Jafari, S. M., Qiao, X., et al. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1929058 · Cited by 37
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling
Hasan, D., Shono, A., van Kalken, C. K., van der Spek, P. J., Krenning, E. P., & Kotani, T. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09814-6 · Cited by 37
Carter, A., Racey, S. N., & Veuger, S. J. (2022) · Applied Sciences · doi:10.3390/app121910161 · Cited by 37
“The potent redox potential of iron allows it to cycle between these di-, tri- and tetravalent states, which makes it crucial in electron transfer and oxygen transport [2].”
BackgroundČerpnjak, K., Pobirk, A. Z., Vrečer, F., & Gašperlin, M. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.015 · Cited by 37
Developability assessment of clinical drug products with maximum absorbable doses
Ding, X. Z., Rose, J. P., & van Gelder, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.02.003 · Cited by 37
“For example, low solubility often drives decision n complex formulations, such as solid dispersions, lipid-based forulations and nanoparticles to enhance absorption (Serajuddin, 999; Porter et al., 2007; Merisko-Liversidge et al., 2004).”
BackgroundPaliperidone-Loaded Self-Emulsifying Drug Delivery Systems (SEDDS) for Improved Oral Delivery
Kanuganti, S., Jukanti, R., Veerareddy, P. R., & Bandari, S. (2012) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2011.574920 · Cited by 37
Tian, Z., Yi, Y., Yuan, H., Han, J., Zhang, X., Xie, Y., Lü, Y., Qi, J., & Wu, W. (2013) · Powder Technology · doi:10.1016/j.powtec.2013.07.010 · Cited by 37
Chatzidaki, M. D., Mateos-Díaz, E., Leal‐Calderon, F., Xenakis, A., & Carrière, F. (2016) · Food & Function · doi:10.1039/c6fo00361c · Cited by 37
Beg, S., Kaur, R., Khurana, R. K., Rana, V., Sharma, T., & Singh, B. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1319-x · Cited by 37
“of drug solubilization capacity and emulsification property (43).”
BackgroundInvestigation of hydrogen bonding in small nucleobases using DFT, AIM, NCI and NBO technique
Mazumdar, P., Kashyap, A., & Choudhury, D. (2023) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2023.114188 · Cited by 36
Mohamad, N.-V. (2023) · Pharmaceuticals · doi:10.3390/ph16101403 · Cited by 36
“They will help the lipid to form micelles [75].”
BackgroundLipid-like properties and pharmacology of the anthelmintic macrocyclic lactones
Lespine, A. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.832200 · Cited by 36
“The intestinal lymphatic system is a net of vessels that typically shadows the blood circulation, and is responsible for the transport of absorbed dietary lipids or lipophilic xenobiotics from the enterocyte to the systemic circulation [24].”
BackgroundInfluentialLipid multilayer microarrays for in vitro liposomal drug delivery and screening
Kusi-Appiah, A. E., Vafai, N., Cranfill, P. J., Davidson, M. W., & Lenhert, S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.023 · Cited by 36
Li, X., Zhao, Z., Yang, Y., Liu, Z., Wang, J., Xu, Y., & Zhang, Y. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02674f · Cited by 36
Ryšánek, P., Grus, T., Šíma, M., & Slanař, O. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02858-0 · Cited by 36
“Intestinal absorption into lymph is an active process involving transport of compounds into enterocytes and subsequent incorporation into chylomicrons and secretion into lacteals, which are blind ended structures that join to mesenteric lymphatic vessels (1).”
BackgroundMethodYe, J.-Y., Chen, Z., Huang, C., Huang, B., Zheng, Y.-R., Zhang, Y., Lu, B., He, L., Liu, C., & Long, X. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s259993 · Cited by 36
Ferreira, L. S., Brito‐Oliveira, T. C., & Pinho, S. C. (2021) · Food Bioscience · doi:10.1016/j.fbio.2021.101455 · Cited by 36
Shete, H. K., Selkar, N., Vanage, G. R., & Patravale, V. B. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.03.056 · Cited by 36
Nanocarriers from dicationic bis-imidazolium amphiphiles and their interaction with anionic drugs
Casal-Dujat, L., Griffiths, P. C., Rodríguez‐Abreu, C., Solans, C., Rogers, S. E., & Pérez‐García, L. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20289e · Cited by 36
Prajapati, H. N., Patel, D. P., Patel, N. G., Dalrymple, D. M., & Serajuddin, A. T. M. (2016) · International Journal of Pharmaceutical Excipients · doi:10.66617/001c.1122 · Cited by 36
Tran, T., Xi, X., Rades, T., & Müllertz, A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.026 · Cited by 36
“4 developed to overcome this problem by presenting lipophilic drugs in solubilized form in the gastro-intestinal tract, in order to avoid the dissolution process, which is often slow or incomplete with a conventional solid dosage form (Porter et al., 2007).”
BackgroundInfluentialDesign and evaluation of self-nanoemulsifying drug delivery systems for nebivolol hydrochloride
Gambhire, M. S., Narkhede, R., & Gujar, K. (2014) · Asian Journal of Pharmaceutics · doi:10.4103/0973-8398.139190 · Cited by 36
Elkhabaz, A., Sarkar, S., Dinh, J., Simpson, G. J., & Taylor, L. S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00814 · Cited by 35
Prospects and Challenges of Phospholipid-Based Prodrugs
Marković, M., Ben‐Shabat, S., Keinan, S., Aponick, A., Zimmermann, E. M., & Dahan, A. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040210 · Cited by 35
“Once they are absorbed into the enterocytes, LPL is re-acylated to PL by the action of the enzyme lysophosphatidylcholine acyltransferase, and due to the amphiphilic nature of the PL it is now involved with stabilization of the surface of lipoproteins, produced in-situ within the enterocyte [20,21].”
BackgroundChaturvedi, S., Verma, A. K., & Saharan, V. A. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.064 · Cited by 35
Rational Selection of Bio-Enabling Oral Drug Formulations – A PEARRL Commentary
Kuentz, M., Holm, R., Kronseder, C., Saal, C., & Griffin, B. T. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.02.004 · Cited by 35
Gausuzzaman, S. A. L., Saha, M., Dip, S. J., Alam, S., Kumar, A., Das, H., Sharker, S. M., Rashid, M. A., Kazi, M., & Reza, H. M. (2022) · Polymers · doi:10.3390/polym14153220 · Cited by 35
“1 and a low LCT solubility, lymphatic transport can still be accomplished when increasing the drug’s lipophilicity [21] or formulating with long-chain lipid-based or lymphatic transportfacilitating excipients [22].”
BackgroundAsfour, M. H., El-Alim, S. H. A., Kassem, A. A., Salama, A., Gouda, A. S., Nazim, W. S., Nashaat, N. H., Hemimi, M., & Meguid, N. A. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02501-2 · Cited by 35
“Accordingly, the developed VD3-NE6 formulation would potentially result in improved VD3 oral bioavailability [24, 25].”
BackgroundMitra, D., Afreen, S., MOHAPATRA, P. K. D., & Abdalla, M. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05489-5 · Cited by 35
Metadata
- Authors
- Porter, C. J. H., Trevaskis, N. L., & Charman, W. N.
- Affiliations
- Monash University (AU)
- Corresponding author
- Porter, Christopher J. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 231-248
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2069235788
- Cited by
- 1,824
- References
- 253
- Citations by year
- 2026: 88 · 2025: 87 · 2024: 67 · 2023: 89 · 2022: 119 · 2021: 108 · 2020: 140 · 2019: 101 · 2018: 117 · 2017: 121 · 2016: 125 · 2015: 119 · 2014: 120 · 2013: 128 · 2012: 94
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lipid-based drug delivery, oral bioavailability, lipophilic drugs, poorly water-soluble drugs, lipid excipients, first-pass metabolism, lipid-based formulations
- MeSH terms
- Administration, Oral, Animals, Pharmaceutical Preparations, Excipients, Humans, Intestinal Absorption, Lipids, Drug Design, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.